ACROSTUDY, a Pfizer-sponsored non-interventional post marketing study on the long-term outcomes of pegvisomant therapy in patients with acromegaly.

Trial Profile

ACROSTUDY, a Pfizer-sponsored non-interventional post marketing study on the long-term outcomes of pegvisomant therapy in patients with acromegaly.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Pegvisomant (Primary)
  • Indications Acromegaly
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ACROSTUDY
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Feb 2017 Results (n=204) published in the European Journal of Endocrinology
    • 04 Apr 2016 Results of effectiveness of first-line Pegvisomant monotherapy (n=204) presented at The 98th Annual Meeting of the Endocrine Society
    • 11 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top